Neurotrope Inc (OTCMKTS:NTRP) shares were down 0.76% to $19.55 then bounced back by 1.02% to $19.75 in after-hours trading on Friday. Share prices have been trading in a 52-week range of $5.76 to $21.76. The company has a market cap of $131.18 million at 6.78 million shares outstanding.
Neurotrope Inc recently announced that it concluded dosing and patient monitoring in its Phase 2 double blind, placebo controlled clinical trial of bryostatin-1 in the treatment of moderate to severe Alzheimer’s dementia. These patients underwent a 12 week treatment with bryostatin-1, followed by a 30-day post-treatment evaluation. The study is designed to assess the therapeutic efficacy of bryostatin-1, a PKC epsilon activator.
“We are very pleased with the execution of the study. It took only about 13 months from initiation of randomization of the study to completion the last patient visit,” Dr. Susanne Wilke, Chief Executive Officer of Neurotrope stated. “A reversal of Alzheimer’s progression would represent a major step forward in the treatment of Alzheimer’s dementia patients after years of failed previous trials by other companies and institutions that predominantly targeted amyloid plaque or tau neurofibrillary tangles. Those trials, thus far, have not achieved a significantly reduced rate of decline or improved cognition in any group of patients diagnosed with Alzheimer’s dementia, mild, moderate, or severe.”
Earlier animal studies have demonstrated bryostatin’s efficacy for restorative synaptogenesis, prevention of neuronal death, and anti-amyloid, anti-tau metabolism via the activation of PKC epsilon.
“Although the pathologic hallmarks of Alzheimer’s disease, extracellular plaques and intracellular tangles at autopsy, are essential to identify those demented patients who had Alzheimer’s dementia, plaques and tangles are not closely related to functional decline. In contrast, the loss of synaptic networks has been found, with numerous autopsy studies, to correlate with the severity of cognitive dysfunction and disease progression,” stated Dr. Daniel Alkon, President and Chief Scientific Officer of Neurotrope. “We, at Neurotrope, believe that the regenerative effects of bryostatin’s treatment on the synapses, as well as bryostatin’s prevention of amyloid and plaque deposition, may not just reduce, but potentially reverse the symptoms, by addressing for the first time many of the major early causes of this devastating disease.”
Neurotrope Inc is a biopharmaceutical company with its product candidates in pre-clinical and clinical development. The company is focused on developing a product platform based upon a drug candidate called bryostatin for the treatment of Alzheimer’s disease (AD), which is in the clinical testing stage.
Bryostatin, which is a protein kinase C (PKC) Alpha and e activator, is also developed for other neurodegenerative or cognitive diseases and dysfunctions, which are in pre-clinical testing. Its second generation PKC activators, such as the Bryologs are meant for the treatment of central nervous system disorders, lysosomal storage diseases, stroke, cardio protection and traumatic brain injury. It develops Bryostatin-1 for the treatment of Alzheimer’s disease along with the rare (Orphan) diseases, such as Fragile X Syndrome and Niemann-Pick Type C. It has completed Phase IIa clinical trials of Bryostatin-1 for the treatment of patients with AD.